To test this hypothesis my laboratory examined the effect of the combination of α-lipoic acid and fidarestat, an aldose reductase inhibitor, on vascular and neural complications in a type 1 diabetic rat model (79). Here, AKR1B1 is linked to type 1 diabetes mellitus.